Nasdaq

Grace Therapeutics Reports Positive Phase 3 STRIVE-ON Trial Results for GTx-104 and Secures $30 Million in Financing; NDA Submission Expected by Mid-2025

Grace Therapeutics announced positive Phase 3 trial results for GTx-104, securing $30 million in funding and plans for NDA submission. Grace Therapeutics, Inc. announced that its Phase 3 STRIVE-ON ...
Seeking Alpha

Grace Therapeutics Announces Results From Pivotal Phase 3 STRIVE-ON Safety Trial of GTx-104 in aSAH

PRINCETON, N.J., Feb. 10, 2025 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (GRCE), formerly Acasti Pharma Inc. (Grace Therapeutics or the Company), a late-stage ...
Seeking Alpha

Grace Therapeutics Pivotal Phase 3 STRIVE-ON Safety Trial Presented at 2025 Neurocritical Care Annual Meeting

PRINCETON, N.J., Sept. 22, 2025 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, ...
Nasdaq

Corcept Announces Primary Endpoint Met in Pivotal Phase 3 GRACE Trial of Relacorilant in Patients With Hypercortisolism (Cushing’s Syndrome)

MENLO PARK, Calif., May 28, 2024 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat ...